142 related articles for article (PubMed ID: 17020565)
1. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent.
Kandzari DE; Leon MB
J Interv Cardiol; 2006 Oct; 19(5):405-13. PubMed ID: 17020565
[TBL] [Abstract][Full Text] [Related]
2. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients.
Gershlick A; Kandzari DE; Leon MB; Wijns W; Meredith IT; Fajadet J; Popma JJ; Fitzgerald PJ; Kuntz RE;
Am J Cardiol; 2007 Oct; 100(8B):45M-55M. PubMed ID: 17950832
[TBL] [Abstract][Full Text] [Related]
3. Development and performance of the zotarolimus-eluting Endeavor coronary stent.
Kandzari DE
Expert Rev Med Devices; 2010 Jul; 7(4):449-59. PubMed ID: 20583882
[TBL] [Abstract][Full Text] [Related]
4. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
Buellesfeld L; Grube E
Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
[TBL] [Abstract][Full Text] [Related]
5. Drug-eluting stents.
García-García HM; Vaina S; Tsuchida K; Serruys PW
Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
[TBL] [Abstract][Full Text] [Related]
6. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
Kandzari DE; Leon MB; Popma JJ; Fitzgerald PJ; O'Shaughnessy C; Ball MW; Turco M; Applegate RJ; Gurbel PA; Midei MG; Badre SS; Mauri L; Thompson KP; LeNarz LA; Kuntz RE;
J Am Coll Cardiol; 2006 Dec; 48(12):2440-7. PubMed ID: 17174180
[TBL] [Abstract][Full Text] [Related]
7. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
[TBL] [Abstract][Full Text] [Related]
8. Coexistent in-stent restenosis, late incomplete stent apposition and mural thrombus in a zotarolimus-eluting stent.
Zhang F; Qian J; Ge J
J Invasive Cardiol; 2008 Aug; 20(8):423-5. PubMed ID: 18688068
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
10. The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III.
Mehta RH; Leon MB; Sketch MH;
Am J Cardiol; 2007 Oct; 100(8B):62M-70M. PubMed ID: 17950834
[TBL] [Abstract][Full Text] [Related]
11. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
Beijk MA; Piek JJ
Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
[TBL] [Abstract][Full Text] [Related]
12. Xience V everolimus-eluting coronary stent.
Kukreja N; Onuma Y; Serruys PW
Expert Rev Med Devices; 2009 May; 6(3):219-29. PubMed ID: 19419279
[TBL] [Abstract][Full Text] [Related]
13. Zotarolimus (ABT-578) eluting stents.
Burke SE; Kuntz RE; Schwartz LB
Adv Drug Deliv Rev; 2006 Jun; 58(3):437-46. PubMed ID: 16581153
[TBL] [Abstract][Full Text] [Related]
14. Drug-eluting coronary stents: many meta-analyses, little benefit.
Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
[TBL] [Abstract][Full Text] [Related]
15. Is there a preferable DES in diabetic patients? A critical appraisal of the evidence.
Byrne RA; Kastrati A
Catheter Cardiovasc Interv; 2008 Dec; 72(7):944-9. PubMed ID: 19021280
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study.
Suttorp MJ; Laarman GJ;
Am Heart J; 2007 Sep; 154(3):432-5. PubMed ID: 17719285
[TBL] [Abstract][Full Text] [Related]
17. Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study.
Meredith IT; Ormiston J; Whitbourn R; Kay IP; Muller D; Popma JJ; Cutlip DE; Fitzgerald PJ;
Am J Cardiol; 2007 Oct; 100(8B):56M-61M. PubMed ID: 17950833
[TBL] [Abstract][Full Text] [Related]
18. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
19. Understanding the drug-eluting stent trials.
Coolong A; Kuntz RE
Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 stent.
Xu B; Zhang Q; Yang YJ; Qiao SB; Zhang RY; Zhang JS; Hu J; Qin XW; Hong T; Li JP; Chen JL; Huo Y; Gao RL; Shen WF
Chin Med J (Engl); 2008 Mar; 121(6):492-7. PubMed ID: 18364131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
